Patient with liver dysfunction while maintained on veno-venous extracorporeal membrane oxygenation should not be overlooked as a potential donor / Mourad M.M.; Reay M.; Muiesan P.; Mirza D.F.; Perera M.T.P.R.. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - ELETTRONICO. - 27:(2014), pp. e50-e53. [10.1111/tri.12290]

Original Citation:
Patient with liver dysfunction while maintained on veno-venous extracorporeal membrane oxygenation should not be overlooked as a potential donor / Mourad M.M.; Reay M.; Muiesan P.; Mirza D.F.; Perera M.T.P.R.. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - ELETTRONICO. - 27:(2014), pp. e50-e53. [10.1111/tri.12290]

Availability:
This version is available at: 2158/1200032 since: 2020-07-07T09:37:38Z

Published version:
DOI: 10.1111/tri.12290

Terms of use:
Open Access
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:
CASE REPORT

Patient with liver dysfunction while maintained on veno-venous extracorporeal membrane oxygenation should not be overlooked as a potential donor

Moustafa M. Mourad, Michael Reay, Paolo Muiesan, Darius F. Mirza and M. Thamara P. R. Perera

The Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston Birmingham, UK

Summary

This report describes transplantation of liver allograft from a circulatory death donor who was supported by veno-venous extracorporeal membrane oxygenation (ECMO) for 14 days and presented with severely altered liver functions. Successful liver transplant was done in a patient with hepatocellular carcinoma (HCC) in the background of primary sclerosing cholangitis. There was immediate graft function and uneventful recovery with stable graft function at 1-year follow-up. This case illustrates the ability of veno-venous ECMO to resuscitate organs in the presence of severe dysfunction, and perhaps, lessons from this case may be incorporated to optimize the condition of organs rescued from these marginal donors and exemplify the use of ECMO in normothermic regional perfusion in donors after circulatory death.

Introduction

Liver transplantation is superior to any other treatment for those with end-stage liver disease or primary liver tumours. Despite the increased transplant activity worldwide, shortage of donor organs remains a problem. Thus, surgeons have resorted to accept marginal donor organs in an attempt to increase the donor pool [1]. Liver dysfunction of donor is usually considered relative contraindication [2]; however, consideration of such grafts with caution allows expansion of donor pool without compromising post-transplant outcome. In the absence of universal acceptance criteria for donors with abnormal liver biochemistry, surgeons consider these by case-by-case basis [3]. One set laboratory data is usually not sufficient to predict the graft function, whereas ‘trend’ of such results provides a global picture of the donor suitability.

The presented case herein is an example of a donor initially presented with highly abnormal organ function prior to the donation. This donor was deemed unsuitable by all other centres. Careful analysis of the donor history revealed improved liver biochemistry while the patient was managed on extracorporeal membrane oxygenation (ECMO) support. Through this manuscript, we aim to report the first case in the literature thus far on successful use of a liver graft from donors after circulatory death (DCD) donor maintained on veno-venous ECMO. This will be discussed in the background rationale for graft acceptance and recipient selection and successful outcomes. It is estimated that treatment is withdrawn in many patients maintained on ECMO annually in the UK and other countries although an exact figure is difficult to predict [4,5]. Careful selection may help utilize some of the organs from these donors and contribute to ease the pressure on transplant wait lists.
Case report

Donor history
A 35-year-old patient (54 kg, blood group O) with 2-year history of idiopathic pulmonary fibrosis and awaiting lung transplantation was admitted to the local hospital with recurrent pneumocystis pneumonia. Patient was appropriately treated with antibiotics, and on the 6th day of admission, patient developed acute respiratory failure secondary to underlying pulmonary fibrosis. This patient was commenced on veno-venous ECMO; meanwhile, cardiac arrest occurred on the 7th day of admission secondary to a pneumothorax. Although successfully resuscitated, the patient was deemed medically unsuitable for lung transplant. Further treatment was deemed futile. Patient was maintained on veno-venous ECMO until the option of organ donation was explored.

Subsequent to cardiac arrest, donor liver function showed high alanine aminotransferase (ALT) >3000 U/l, which progressively improved to 229 U/l the day before organ offering. Immediate preprocurement donor ALT, alkaline phosphatase and bilirubin were 97 U/l, 172 U/l and 20 µM, respectively. Patient maintained core body temperature of 36.4 °C and oxygen saturation 99% through ECMO support. There was continuous infusion of inotropes. The organ offer was declined by other centres primarily due to liver dysfunction evident from laboratory results. When offered, careful review of the history and the laboratory data convinced us the improving liver function while the patient was on ECMO. The extracorporeal oxygenation was considered a reassurance; hence, the organ offer was accepted.

Donor treatment withdrawal entailed discontinuation of ECMO support, inotropes and extubation. Circulatory death ensued soon after treatment withdrawal, and the donor warm ischaemia time was 32 min. Organs were recovered in the modified super-rapid technique. University of Wisconsin (UW) solution was used for organ preservation. A soft, well-perfused liver graft was procured that showed normal anatomy, no steatosis or injuries. Graft weight was 1203 g.

Recipient
The unit adopts a policy of allocating high-risk organs to recipients without advanced liver disease. Thus, a 59-year-old patient with hepatocellular carcinoma in the background of primary sclerosing cholangitis was selected. The recipient operation was standard. Total cold ischaemia time was 06:15 hours. Implantation time was 28 min with total operative time of 05:40 hours. There was no evidence of postreperfusion syndrome during the reperfusion, and patient remained stable throughout the operation. No packed red blood cell or plasma was given intraoperatively, and final haemoglobin at the time of closure was 9.8 g/dl. Immediate post-operative recovery was excellent. Aspartate transaminase and ALT peaked at 549 and 884 U/l, respectively, following transplantation (Fig. 1). He was diagnosed with acute cellular rejection on day 5 and successfully treated with pulsed steroids. All graft functions were normalized at 14 days following transplantation, and patient now completes 1 year with stable graft function.

Discussion
Shortage of donor organs has been largely contributed by expanding the criteria, and indications for transplantation and marginal grafts are widely used in this background. Through ‘utilitarian approach’ practised in our unit, ideal donor–recipient matching could be performed when marginal grafts are used. Blood group-O-recipients at present face fierce competition for organs, and current wait times for a deceased donor graft in the UK for such recipients is 199 days [6]. Nearly 20% of these drop out due to disease progression, tumour growth or medically unsuitable for transplantation [7]. Therefore, any blood group-O-donor could be considered a potential resource unless proven otherwise. The advantage of utilizing the marginal organs in a utilitarian approach is the less competition it creates for those remaining on the wait list when a suitable, ideal quality graft becomes available.

Use of liver grafts from donors with abnormal liver biochemistry is not a new concept. Liver grafts with altered liver functions offer survival chance for many patients and help reduce mortality and dropout on the waiting lists [8]. Of 388 liver transplant recipients who received grafts from extended criteria donors, 20.5% were from donors with raised liver function tests, yet outcomes were comparable.
Organ donor supported by ECMO

Mourad et al.

with standard donors [8]. Therefore, the previously considered relative contraindication to use grafts from those with abnormal liver biochemistry is currently revisited by many centres.

The successful use of liver graft from the donor presented herein is attributable to ECMO. Considerable period of artificial oxygenation allowed the ischaemic insult to the liver from cardiac arrest to recover. ECMO is generally used as arterio-venous ECMO for both cardiac and respiratory support or as veno-venous ECMO, which only support oxygenation of tissues [9]. It has been demonstrated that pulsatile blood flow was of considerable importance to hepatic and renal function with more efficient perfusion [10]. In this donor, ECMO maintained efficient perfusion and oxygenation of potentially transplantable organs.

Johnson et al. [11] reported first ever liver transplant from a donor who was maintained on veno-venous ECMO for 29 days, and this was a donation after brain death (DBD) where there was no warm ischaemia involved, and presented case is the first successful use of a liver graft from DCD donor maintained on veno-venous ECMO; predonation ECMO provided the reassurance to use this graft, and this decision was influenced by recent interest on application of ECMO as bridge to organ donation between asystole and procurement, reversing anaerobic metabolism mimicking a period of ischaemic preconditioning [12]. In a previously reported DCD donor, however, arterio-venous ECMO had been successfully used, albeit for a much shorter duration. ECMO permits the assessment of donor organs under nonischaemic conditions over a period of time through biochemical means, reflecting the ability of liver graft to recover from warm ischaemic injury in Maastricht category II DCD donors [13] (Table 1). This principle was recently introduced in the UK in Maastricht category III DCD donors by some groups, including author’s institution using a modified organ procurement protocol [19] in the form of regional perfusion involving abdominal compartment (normothermic regional perfusion – NRP). A recent systemic review consolidated the evidence for regional organ perfusion with ECMO of DCD organs from ischaemic injury and enables transplantation with acceptable survival [20]. Although NRP protocols recommend shorter period of organ perfusion than the longer use of ECMO in the presented case, the lessons from this case may probably help justify the use of NRP in DCD donors.

In summary, we present the first successful use of liver graft from a DCD donor with significantly altered biochemistry and maintained on veno-venous ECMO. Organ functions improved while maintained on ECMO prior to donation, and the clinical sequelae following transplantation was parallel with that of any standard liver transplant. In the era of organ shortage, consideration of those maintained on ECMO for a considerable time period before treatment is withdrawn may add few extra organs to the donor pool.

Authorship

MM: responsible for data collection. MM and MTPRP: case report design, prepared the manuscript. MTPRP: acceptance of donor and performing transplant. MR, PM, DFM and MTPRP: patient management, data interpretation and critical review of manuscript; all co-authors approved the final manuscript.

Funding

The investigators have not received any financial support for this case report. None of the authors has any potential conflicting financial interests relevant to this report.

Table 1. The use of ECMO in the different literatures to support liver grafts prior to organ harvest.

<table>
<thead>
<tr>
<th>Timing of ECMO</th>
<th>Type of ECMO</th>
<th>Donor type</th>
<th>Number of cases</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to death (predonation)</td>
<td>Arterio-venous</td>
<td>DCD [14]</td>
<td>1</td>
<td>Excellent immediate function, 2-year follow-up</td>
</tr>
<tr>
<td></td>
<td>Veno-venous</td>
<td>DBD [11]</td>
<td>1</td>
<td>Excellent immediate function, follow-up N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCD*</td>
<td>1</td>
<td>Excellent immediate function, 1-year follow-up</td>
</tr>
<tr>
<td>Post-mortem (postcardiac death)</td>
<td>Abdominal regional perfusion – normothermic regional perfusion</td>
<td>DCD (II)† [15]</td>
<td>34 (8.5%)‡</td>
<td>82% 1-year overall survival/70% 1-year graft survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCD (III)†</td>
<td>14 (N/A)</td>
<td>71% 1-year overall survival/43% 1-year graft survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCD (III)†</td>
<td>12 (63%)</td>
<td>91% 1-year overall survival/91% 1-year graft survival</td>
</tr>
</tbody>
</table>

DCD, donors after circulatory death; ECMO, extracorporeal membrane oxygenation; N/A, not available.

*Presented case in this report.
†Maastricht category II and III DCD.
‡Percentage of successful liver graft procurement using ECMO in relation to the total number of potential donors.
Ethical
Not applicable.

References